ADMA

#1975
ADMA Biologics Inc - Common Stock
9.3 9 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
9.25
9.42
Intervallo Annuale
7.21
20.46
Variazione giornaliera
-1.48%
Variazione Mensile
+9.31%
Variazione di 6 mesi
-40.19%
Variazione Annuale
-45.06%
Chiusura Precedente
9.3 4
Open
9.2 5
Minimo
9.2 5
Massimo
9.4 2
Volume
212
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
ADMA BIOLOGICS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
ADMA BIOLOGICS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
ADMA BIOLOGICS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K

ADMA BIOLOGICS, INC. current report, Q4 FY2024

Full document

ADMA Biologics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by ADMA Biologics, Inc. (Nasdaq: ADMA) on January 2, 2025, reporting events occurring on December 30, 2024. The filing addresses corporate governance changes specifically regarding the Board of Directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.

Material Changes

The primary material change reported is the appointment of a new director:

  • Appointment: Eduardo Rene Salas was appointed to the Board of Directors as a Class I director.
  • Term: His term expires at the Company's 2026 annual meeting of stockholders.
  • Background: Mr. Salas brings extensive financial executive experience, including prior roles as CFO of Wellstat Therapeutics, LLC, lead independent director of Embody, Inc., and a senior audit partner at Ernst & Young LLP.

Guidance, Outlook, and Compensation

The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. Regarding compensation for the new appointment:

  • Mr. Salas is eligible to participate in the 2022 Equity Compensation Plan.
  • He will receive an initial grant of options to purchase 20,011 shares of common stock upon joining the Board.
  • Additional compensation will follow the Company's general policies for non-employee directors.

Investor Verification Checklist

  • Verify the effective date of Mr. Salas' board appointment and his specific committee assignments (if any).
  • Review the Company's 2022 Equity Compensation Plan to understand the vesting schedule and exercise price of the 20,011 option grant.
  • Confirm the composition of the Board of Directors following this appointment to assess independence and expertise balance.
  • Check for any subsequent filings regarding Mr. Salas' participation in audit or other key committees.

Notizie